Physician profile
Tom K Lin
NPI 1114136934
$10,083.23
in general payments reported to CMS, 2019-2025
15 companies · $5,203 in 2025
The $5,203 reported for 2025 was more than what 90% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $293 · 2021: $294 · 2022: $1,374 · 2023: $202 · 2024: $2,454 · 2025: $5,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,876 · Food and Beverage: $776 · Travel and Lodging: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,875.50 |
| Food and Beverage | $776.18 |
| Travel and Lodging | $207.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $3,855.00 | 2024-2025 | Evis Exera III Duodenovideoscope |
| Fujifilm Healthcare Americas Corporation | $2,320.50 | 2025 | |
| Boston Scientific Corporation | $880.78 | 2021-2025 | Axios |
| Pentax of America, INC. | $700.00 | 2025 | |
| Philips North America LLC | $659.79 | 2022 | |
| Canon Medical Systems USA, INC. | $542.79 | 2022 | |
| Ambu INC. | $488.95 | 2020-2022 | |
| Abbvie INC. | $251.67 | 2019-2020 | |
| Alcresta Therapeutics, INC. | $237.40 | 2019-2024 | Relizorb |
| Mirum Pharmaceuticals, INC. | $45.40 | 2024 | Livmarli |
| Qol Medical, LLC | $44.57 | 2025 | Sucraid |
| Genzyme Corporation | $27.33 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $15.45 | 2023 | Dysport |
| Celltrion USA INC. | $13.60 | 2025 | Vegzelma |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.